Jefferies Starts RxSight Inc. (RXST) at Buy

Jefferies analyst Young Li initiates coverage on RxSight Inc. (NASDAQ: RXST) with a Buy rating and a price target of $72.00.

The analyst comments: "RXST makes the first and only post surgery adjustable IOL to resolve cataracts. The differentiated and best in class tech enables premium IOL (AT-IOL) TAM expansion, and share taking, from 10% US (3% WW) share to 50%+ US LT. While our survey and checks don't focus explicitly on 3Q, the proprietary survey and surgeon checks suggest above cons growth for '25E+. We also expect EBITDA to turn positive by 2H26. We initiate at Buy with a $72 PT."

For an analyst ratings summary and ratings history on RxSight Inc. click here. For more ratings news on RxSight Inc. click here.

Shares of RxSight Inc. closed at $50.25 yesterday.

You May Also Be Interested In

• Citi Upgrades Grupo Aeroportuario del Pacifico SAB de CV (GAPB:MM) (PAC) to Buy
• Penguin Solutions closes $750M convertible notes offering due 2031
• ACI Worldwide exploring sale of billing division - Reuters